End-of-day quote
Korea S.E.
23:00:00 27/06/2024 BST
|
5-day change
|
1st Jan Change
|
4,775
KRW
|
-6.00%
|
|
-16.37%
|
+29.05%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,440,309
|
307,059
|
245,547
|
Enterprise Value (EV)
1 |
1,460,950
|
202,123
|
165,470
|
P/E ratio
|
-7.92
x
|
-5.72
x
|
11.1
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
57
x
|
7.26
x
|
3.03
x
|
EV / Revenue
|
57.9
x
|
4.78
x
|
2.04
x
|
EV / EBITDA
|
-176
x
|
-40.5
x
|
11.7
x
|
EV / FCF
|
-
|
-8,779,752
x
|
-254,632,267
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
Price to Book
|
27.6
x
|
1.67
x
|
1.17
x
|
Nbr of stocks (in thousands)
|
51,532
|
66,034
|
66,364
|
Reference price
2 |
27,950
|
4,650
|
3,700
|
Announcement Date
|
23/03/23
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net sales
1 |
25,249
|
42,303
|
80,997
|
EBITDA
1 |
-8,290
|
-4,990
|
14,172
|
EBIT
1 |
-11,235
|
-10,097
|
6,046
|
Operating Margin
|
-44.5%
|
-23.87%
|
7.46%
|
Earnings before Tax (EBT)
1 |
-225,900
|
-45,853
|
17,711
|
Net income
1 |
-176,267
|
-44,705
|
25,686
|
Net margin
|
-698.13%
|
-105.68%
|
31.71%
|
EPS
2 |
-3,527
|
-812.7
|
334.0
|
Free Cash Flow
|
-
|
-23,021
|
-649.8
|
FCF margin
|
-
|
-54.42%
|
-0.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
23/03/23
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2023 Q3
|
---|
Net sales
1 |
13.85
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
14/11/23
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net Debt
1 |
20,641
|
-
|
-
|
Net Cash position
1 |
-
|
104,936
|
80,078
|
Leverage (Debt/EBITDA)
|
-2.49
x
|
-
|
-
|
Free Cash Flow
|
-
|
-23,021
|
-650
|
ROE (net income / shareholders' equity)
|
-
|
-37%
|
12.9%
|
ROA (Net income/ Total Assets)
|
-
|
-3.44%
|
1.61%
|
Assets
1 |
-
|
1,300,801
|
1,592,935
|
Book Value Per Share
2 |
1,014
|
2,786
|
3,157
|
Cash Flow per Share
2 |
642.0
|
1,727
|
1,030
|
Capex
1 |
8,143
|
18,057
|
8,236
|
Capex / Sales
|
32.25%
|
42.68%
|
10.17%
|
Announcement Date
|
23/03/23
|
23/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +29.05% | 230M | | +2.99% | 95.18B | | -4.34% | 37.55B | | -10.41% | 33.75B | | +75.79% | 28.2B | | -14.61% | 15.63B | | -3.46% | 13.63B | | -12.31% | 11.5B | | +184.77% | 10.81B | | -54.13% | 9.23B |
Biopharmaceuticals
|